Sandor Victor 4

What Happened
Sandor Victor, a director of AbCellera Biologics Inc. (ABCL), was granted a derivative award of 152,207 shares on July 1, 2026. The award shows a grant price of $0.00 (i.e., no cash paid at grant). This is a non-sale award (not an open-market purchase or sale), so no immediate cash changed hands.

Key Details

• Transaction date: July 1, 2026; Filing date (Form 4): July 6, 2026 (appears later than the typical 2-business-day Form 4 deadline).
• Transaction code: A (award/grant); reported price: $0.00; number of shares/units: 152,207 (classified as a derivative).
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote: The award vests in substantially equal annual installments over three years, with the first tranche vesting July 1, 2027, subject to the reporting person’s continuous service.
• No indication in the filing that shares were sold, exercised, or used to cover taxes at grant.

Context
This was an equity award (derivative grant) to a director that will vest over time; it does not represent an immediate purchase or sale and does not provide immediate cash proceeds. For retail investors, grants like this are common for compensation/retention and should be interpreted as part of long-term incentive arrangements rather than a direct signal to buy or sell the stock.